SNDX Q4 2023 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$78M

Net Income

-$72M

EPS (Diluted)

$-1.00

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$613M

Total Liabilities

$59M

Stockholders' Equity

$554M

Cash & Equivalents

$295M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$78M	-$42M	-85.3%
Net Income	-$72M	-$39M	-84.9%